NeuroMetrix, Inc. Announces Conference Call to Discuss American Diabetes Association 72nd Scientific Sessions and Other Business ActivitiesWALTHAM, Mass.--(BUSINESS WIRE)--Jun. 18, 2012--
NeuroMetrix, Inc. (Nasdaq: NURO),
www.neurometrix.com,
today said it will host a conference call at
10:00 a.m., Eastern Time on
June 20, 2012 to discuss the highlights of its recent participation in
the
American Diabetes Association 72
nd Scientific Sessions
and other business activities.
The conference call may be accessed in the United States by dialing
800-299-9630 and using the confirmation code 66482813. Internationally,
the conference call may be accessed by dialing 617-786-2904 and using
the same confirmation code.
A replay of the conference call will be available starting two hours
after the call by dialing 888-286-8010, domestically and 617-801-6888,
internationally. The confirmation code to access the replay is 15103396.
The replay will be available for three months after the conference call.
About NeuroMetrix
NeuroMetrix is an innovative medical device company that develops and
markets home use and point-of-care devices, associated consumables, and
support software for the treatment and management of diabetes and its
complications. The company is focused on nerve related complications of
diabetes, called diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot
ulcers that may require amputation, cause disabling pain, and increase
the risk of falling in the elderly. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company’s products are used by physicians and other clinicians, in
retail health settings such as pharmacies, and by managed care
organizations to optimize patient care and reduce healthcare costs. The
company markets the NC-stat® DPNCheck™ device,
which is a rapid, accurate, and quantitative point-of-care test for
diabetic neuropathy. This product is used to detect diabetic neuropathy
at an early stage and to guide treatment. The company is in late stage
development of SENSUS™, a pain management device that will be
used to treat painful diabetic neuropathy, a form of chronic intractable
pain. Currently, painful diabetic neuropathy is treated
pharmacologically, which is a $2 billion annual market. The company has
additional therapeutic products in its pipeline. For more information,
please visit http://www.neurometrix.com.
Source: NeuroMetrix, Inc.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
